Regeneron Pharmaceuticals Inc. diskutieren

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Morgan Stanley from $1,235.00 to $1,184.00. They now have an "overweight" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $1,150.00 to $1,000.00. They now have an "outperform" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) is now covered by analysts at Wolfe Research. They set an "outperform" rating and a $1,150.00 price target on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) was upgraded by analysts at Wolfe Research to a "strong-buy" rating.

Hey there, fellow investor! So, Regeneron's had a bit of a rough patch lately, huh? That new eye drug isn't quite flying off the shelves as expected. But you know what? I'm still bullish on this biotech powerhouse. Why, you ask? Well, it's like they've hit a speed bump, not a wall. Sure, the high-dose Eylea sales are lagging, and those pesky biosimilars are lurking around the corner. But let's not forget Regeneron's track record of innovation. They're like that scrappy startup that grew up but never lost its mojo. Remember how they knocked it out of the park with their COVID antibody cocktail? That's the kind of ingenuity that keeps me excited about their future. Plus, with their diverse pipeline, they're not putting all their eggs in one basket. It's a bit like a biotech buffet – if one dish doesn't satisfy, there's always another to try. So, while the market's giving Regeneron the stink eye right now, I'm seeing an opportunity. It might be a bumpy ride, but I think there's still plenty of growth potential here. Just don't forget your seatbelt!

Alright, let's dive into Regeneron, shall we? Sure, their stock took a bit of a nosedive recently, but I'm not throwing in the towel just yet. Think of it like a roller coaster - we're just at a low point before the next thrilling climb. The new eye disease drug sales might be lagging, but hey, Rome wasn't built in a day, right? Regeneron's got a solid track record of innovation, and I've got a hunch they'll bounce back. It's like they're planting seeds now that'll grow into mighty oaks later. The current price feels like a bargain to me. Despite the recent setback, their overall pipeline and potential still look promising. Isn't it often darkest before the dawn? I'm thinking this could be a golden opportunity to get in while others are panicking. Remember, in the world of biotech, today's stumble could be tomorrow's breakthrough!

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Sanford C. Bernstein from $1,110.00 to $1,070.00. They now have an "outperform" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Truist Financial Co. from $1,126.00 to $1,004.00. They now have a "buy" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Wells Fargo & Company from $1,050.00 to $900.00. They now have an "overweight" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Piper Sandler from $1,195.00 to $1,013.00. They now have an "overweight" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at BMO Capital Markets from $950.00 to $903.00. They now have an "overweight" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00. They now have an "overweight" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $1,019.00 to $917.00. They now have a "buy" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Bank of America Co. from $575.00 to $547.00. They now have an "underperform" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Truist Financial Co. from $1,004.00 to $975.00. They now have a "buy" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at BMO Capital Markets from $865.00 to $800.00. They now have an "outperform" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Wells Fargo & Company from $750.00 to $700.00. They now have an "overweight" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Royal Bank of Canada from $1,051.00 to $943.00. They now have an "outperform" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $917.00 to $804.00. They now have a "buy" rating on the stock.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) had its price target lowered by analysts at Truist Financial Co. from $975.00 to $940.00. They now have a "buy" rating on the stock.